Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook
As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its orthopaedics business. Together, these moves are reshaping the investment case for JNJ as it heads into 2026. Below is a news-style rundown of the latest price action, fundamentals, pipeline news, Wall Street forecasts and key risks that matter for Johnson & Johnson stock today. JNJ stock today: Price, market cap and performance in 2025 On performance, JNJ has easily outpaced